LC 280391Alternative Names: LC-280391
Latest Information Update: 07 Oct 2015
At a glance
- Originator LG Life Sciences
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2015 Preclinical trials in Type-2 diabetes mellitus in CHina (unspecified route)
- 28 Aug 2015 LC 280391 is available for licensing as of 28 Aug 2015. http://china.lgls.com/